| 2014-01-09 |
Vertex Pharmaceuticals Incorporated |
Vertex Announces Sustained Viral Response Rate (SVR4) Data from All-Oral Study of VX-135 in Combination with Daclatasvir in Hepatitis C vrtx.com ↗ |
| 2013-07-25 |
Vertex Pharmaceuticals Incorporated |
Vertex Provides Update on Ongoing All-Oral Studies of VX-135 in Hepatitis C vrtx.com ↗ |
| 2013-04-23 |
Vertex Pharmaceuticals Incorporated |
ALS-2200 (VX-135) Viral Kinetic Study Shows Significant Reduction in HCV RNA in People with Genotype 1 Hepatitis C Virus Infection and Cirrhosis, and in People with Genotypes 2, 3 or 4 HCV Infection vrtx.com ↗ |
| 2013-04-05 |
Vertex Pharmaceuticals Incorporated |
Vertex Enters Agreement with Bristol-Myers Squibb for Phase 2 All-Oral Studies of VX-135 in Combination with Daclatasvir for the Treatment of Hepatitis C vrtx.com ↗ |
| 2012-11-10 |
Vertex Pharmaceuticals Incorporated |
Data from Viral Kinetic Study Showed Rapid Reduction of HCV RNA with ALS-2200 (VX-135), Vertex's Oral Nucleotide Analogue in Development for the Treatment of Hepatitis C vrtx.com ↗ |
| 2012-11-01 |
Vertex Pharmaceuticals Incorporated |
Vertex Enters Agreement with GlaxoSmithKline for Phase 2 All-Oral Study of VX-135 and GSK2336805 for the Treatment of Hepatitis C vrtx.com ↗ |
| 2012-11-01 |
Vertex Pharmaceuticals Incorporated |
Vertex Announces Collaboration with Janssen To Initiate Phase 2 All-Oral Study of VX-135 and Simeprevir (TMC435) for the Treatment of Hepatitis C vrtx.com ↗ |